For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study ...

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 mg is efficacious and tolerable.

CKD and ESRD can have unpleasant cutaneous manifestations, including alopecia, but there are several helpful approaches to mitigating hair loss.

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...

Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.

Bempikibart demonstrated positive, durable responses among patients with severe to very severe alopecia areata, according to ...

Masumi Tsunoda, a 45-year-old woman in Maebashi, Gunma Prefecture, who is an alopecia areata patient, was asked to design a headscarf for Licca-chan. Tsunoda contracted the disease 10 years ago.

The rising prevalence of prediabetes among young adults signals early metabolic dysfunction, significantly increasing the ...

Significantly more patients receiving baricitinib 2 mg, 4 mg had SALT score ≤20, ≤10 versus placebo at week 36 ...